What is the initial treatment approach for Immune Thrombocytopenia (ITP)?

The initial treatment approach for Immune Thrombocytopenia (ITP) focuses on using corticosteroids. Corticosteroids, such as prednisone, work by modulating the immune response. In cases of ITP, the immune system mistakenly destroys platelets; corticosteroids help reduce this autoimmune activity by decreasing the production of autoantibodies against platelets, ultimately leading to an increase in the platelet count.

This approach is often preferred as it is non-invasive and can be effective in managing the disease, especially in cases where the patient is experiencing mild to moderate symptoms. Choosing corticosteroids allows for the treatment to be adjusted based on the patient's clinical response and overall health status. It's crucial to have an initial management strategy that can be rapidly deployed to control platelet counts and minimize bleeding risks.

While platelet transfusions can temporarily raise platelet levels, they are not effective in ITP because the underlying issue is the destruction of platelets, not a deficiency. Intravenous Immunoglobulin (IVIG) may also be used, particularly in acute situations or for rapid response, but it is not the first-line treatment for chronic ITP. Splenectomy is a more invasive surgical option that may be considered for patients who do not respond to medical therapy,